43 Advanced Solid Tumors Clinical Trials in Chicago, IL (2026)

Q: How do I join a clinical trial in Chicago?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Chicago research site will contact you.

Recruiting Advanced Solid Tumors Studies in Chicago

NCT06172478Recruiting

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma ...

Chicago, ILPHASE2740 participantsDaiichi Sankyo

View Study Details

NCT05417594Recruiting

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participan...

Chicago, ILPHASE1695 participantsAstraZeneca

View Study Details

NCT06311214Recruiting

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

This phase II ADC MATCH screening and multi-sub-study treatment trial is evaluating whether biomarker-directed treatment with one of three antibody-drug conjugates (ADCs) (sacituzumab govitecan, enfor...

Chicago, ILPHASE2500 participantsNational Cancer Institute (NCI)

View Study Details

NCT04665206Recruiting

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients wit...

Chicago, ILPHASE1434 participantsVivace Therapeutics, Inc

View Study Details

NCT06465069Recruiting

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The ...

Chicago, ILPHASE1420 participantsEli Lilly and Company

View Study Details

NCT06619587Recruiting

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

This is a first-in-human Phase I/II, open-label, multicenter, dose-escalation and expansion study designed to evaluate the safety, pharmacokinetics, and preliminary activity of GDC-7035 as a single ag...

Chicago, ILPHASE1410 participantsGenentech, Inc.

View Study Details

NCT06545331Recruiting

Study of XB010 in Subjects With Solid Tumors

This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with lo...

Chicago, ILPHASE1396 participantsExelixis

View Study Details

NCT06635785Recruiting

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors....

Chicago, ILPHASE1387 participantsOncoC4, Inc.

View Study Details

NCT03686124Recruiting

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

The study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expres...

Chicago, ILPHASE1375 participantsImmatics US, Inc.

View Study Details

NCT05533697Recruiting

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab....

Chicago, ILPHASE1361 participantsModernaTX, Inc.

View Study Details

NCT06554795Recruiting

First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors

A Phase 1/2a First-in-Human Study of DB-1419 in Advanced/Metastatic Solid Tumors...

Chicago, ILPHASE1360 participantsDualityBio Inc.

View Study Details

NCT06241456Recruiting

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in pa...

Chicago, ILPHASE1351 participantsFate Therapeutics

View Study Details

NCT05315700Recruiting

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-...

Chicago, ILPHASE1350 participantsORIC Pharmaceuticals

View Study Details

NCT06265727Recruiting

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4. The main questions it aims to answe...

Chicago, ILPHASE1348 participantsCorbus Pharmaceuticals Inc.

View Study Details

NCT05557045Recruiting

A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815

This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway....

Chicago, ILPHASE1332 participantsJazz Pharmaceuticals

View Study Details

NCT05720117Recruiting

A Study of PYX-201 in Advanced Solid Tumors

The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (OR...

Chicago, ILPHASE1330 participantsPyxis Oncology, Inc

View Study Details

NCT06840886Recruiting

A Study of PHST001 in Advanced Solid Tumors

This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy...

Chicago, ILPHASE1272 participantsPheast Therapeutics

View Study Details

NCT04295863Recruiting

Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers

A randomized research study of drugs nivolumab and pembrolizumab in patients with locally advanced or metastatic cancers. Based on data from earlier studies it appears that the drugs can be given less...

Chicago, ILPHASE1264 participantsUniversity of Chicago

View Study Details

NCT06413680Recruiting

A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies

This study is researching an experimental drug called REGN10597 (called "study drug"). The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study i...

Chicago, ILPHASE1240 participantsRegeneron Pharmaceuticals

View Study Details

NCT06480552Recruiting

An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

The primary objectives of this trial are to: * Characterize the safety and tolerability of TEV-56278 * Determine the Recommended Phase 2 Dose (RP2D) * Evaluate antitumor activity of TEV-56278 (Part 2...

Chicago, ILPHASE1240 participantsTeva Branded Pharmaceutical Products R&D LLC

View Study Details

NCT05732831Recruiting

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is...

Chicago, ILPHASE1225 participantsTango Therapeutics, Inc.

View Study Details

NCT04939610Recruiting

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

Fibroblast activation protein (FAP) is a cell surface protein that is highly expressed on the surface of cancer-associated fibroblasts (CAFs) present in the tumor microenvironment of most epithelial c...

Chicago, ILPHASE1222 participantsNovartis Pharmaceuticals

View Study Details

NCT06795412Recruiting

Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

The primary objective of this study is to determine the recommended Phase 2 doses (RP2D(s)) and maximum tolerated dose (MTD) of PYX-201 in combination with pembrolizumab for participants with advanced...

Chicago, ILPHASE1220 participantsPyxis Oncology, Inc

View Study Details

NCT06244485Recruiting

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

This study will evaluate the safety, tolerability, and efficacy of valemetostat tosylate in combination with DXd ADC in patients with advanced solid tumors....

Chicago, ILPHASE1210 participantsDaiichi Sankyo

View Study Details

NCT06810544Recruiting

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an op...

Chicago, ILPHASE1191 participantsTango Therapeutics, Inc.

View Study Details

NCT07169734Recruiting

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P...

Chicago, ILPHASE1180 participantsAlentis Therapeutics AG

View Study Details

NCT06747585Recruiting

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

Chicago, ILPHASE1170 participantsAlentis Therapeutics AG

View Study Details

NCT06603844Recruiting

First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

The purpose of this study is to determine the safety, blood concentrations and treatment effect of CRB-601 in combination with immunotherapy in patients who have advanced solid tumors (cancer) and hav...

Chicago, ILPHASE1156 participantsCorbus Pharmaceuticals Inc.

View Study Details

NCT07428278Recruiting

Resilience-Building for Advance Care Planning

The aims of this study are to (1) assess the feasibility, acceptability, and usability of the ROCKS intervention among patients with advanced cancer and their family caregivers through a randomized co...

Chicago, ILNA152 participantsUniversity of Illinois at Chicago

View Study Details

NCT04851119Recruiting

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to tr...

Chicago, ILPHASE1147 participantsChildren's Oncology Group

View Study Details

NCT05873686Recruiting

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected...

Chicago, ILPHASE1140 participantsNuvectis Pharma, Inc.

View Study Details

NCT06898450Recruiting

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

The goal of this clinical trial is to learn if NDI-219216 is safe for patients, and if NDI-219216 might be a possible treatment for advanced solid tumors in the later phases of the study. The main qu...

Chicago, ILPHASE1134 participantsNimbus Wadjet, Inc.

View Study Details

NCT05394103Recruiting

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monother...

Chicago, ILPHASE1130 participantsQurient Co., Ltd.

View Study Details

NCT06014658Recruiting

Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors

This is a first-in-human (FIH), open label Phase 1/1b / Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment. Phase 1 will identify potential optimal biolog...

Chicago, ILPHASE1130 participantsMBrace Therapeutics

View Study Details

NCT06395519Recruiting

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor acti...

Chicago, ILPHASE1120 participants858 Therapeutics, Inc.

View Study Details

NCT07196644Recruiting

A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab ad...

Chicago, ILPHASE2100 participantsAbbVie

View Study Details

NCT06778863Recruiting

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation....

Chicago, ILPHASE190 participantsClasp Therapeutics, Inc.

View Study Details

NCT06620302Recruiting

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

This phase I/II trial tests the safety, side effects and best dose of DT2216 in combination with irinotecan and how well it works in treating children, adolescents and young adults with solid tumors a...

Chicago, ILPHASE181 participantsChildren's Oncology Group

View Study Details

NCT04870944Recruiting

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has c...

Chicago, ILPHASE163 participantsChildren's Oncology Group

View Study Details

NCT06463340Recruiting

Study of SGR-3515 In Participants With Advanced Solid Tumors.

The purpose of this study is to learn about the effects of a new study drug, called SGR-3515 that may be a treatment for advanced solid tumors....

Chicago, ILPHASE152 participantsSchrödinger, Inc.

View Study Details

NCT07269080Recruiting

STM-06: POLARIS-POlymetastic Lesion Ablative Radiotherapy With Immunotherapy Study

This is a non-randomized two-arm trial, specifically a pilot study in which patients with advanced solid tumor cancer with 3-10 metastatic lesions who are on immunotherapy will receive ablative RT to ...

Chicago, ILPHASE128 participantsUniversity of Illinois at Chicago

View Study Details

NCT05645523Recruiting

Indocyanine Green (ICG) Guided Sentinel Lymph Node Mapping for Pediatric Visceral Solid Tumors

The purpose of the study is to find out the usefulness and safety of a dye called Indocyanine Green (ICG for short). This dye will be used to help the surgeon find lymph nodes draining solid tumors in...

Chicago, ILEARLY_PHASE125 participantsSt. Jude Children's Research Hospital

View Study Details

NCT07036133Recruiting

Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment

This purpose of this study is to help to evaluate the pharmacokinetic (PK) profile of pralatrexate when administered to patients with various degrees of hepatic impairment and to evaluate the safety a...

Chicago, ILPHASE124 participantsAcrotech Biopharma Inc.

View Study Details

About Advanced Solid Tumors Clinical Trials in Chicago

Advanced solid tumors refer to cancers that have grown beyond the original site or spread to distant organs. Many clinical trials enroll patients with various types of advanced solid tumors to test novel therapies. These trials often investigate immunotherapy, targeted therapy, and combination approaches.

There are currently 43 advanced solid tumors clinical trials recruiting participants in Chicago, IL. These studies are seeking a combined 10,795 participants. Research is being sponsored by Daiichi Sankyo, AstraZeneca, National Cancer Institute (NCI) and 32 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Advanced Solid Tumors Clinical Trials in Chicago — FAQ

Are there advanced solid tumors clinical trials in Chicago?

Yes, there are 43 advanced solid tumors clinical trials currently recruiting in Chicago, IL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Chicago?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Chicago research site will contact you about next steps.

Are clinical trials in Chicago free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Chicago studies also compensate for your time and travel.

What advanced solid tumors treatments are being tested?

The 43 active trials in Chicago are testing new therapies including novel drugs, biologics, and treatment approaches for advanced solid tumors.

Data updated July 16, 2026 from ClinicalTrials.gov